Safety Assessment of Gadoversetamide (OptiMARK®) Administered by Power Injector

Journal of Magnetic Resonance Imaging

Volumn 19, Issue 1, 2004, Pages 133-140

  Abdou, Nancy ^a   Napoli, Alicia M ^b   Hynes, Michael R ^b   Allen Jr , John C ^b   Wible Jr , James H ^b  

^a IQVIA   (United States)

^b Tyco Healthcare   (United States)

Author keywords

Contrast enhancement; Gadolinium (Gd); Gadoversetamide; Injection rate; Magnetic resonance imaging (MRI); OptiMARK ; Power injection; Safety

Indexed keywords

GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CONTRAST ENHANCEMENT; DEVICE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION PAIN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TASTE DISORDER;

ANALYSIS OF VARIANCE; CONTRAST MEDIA; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; ORGANOMETALLIC COMPOUNDS; POISSON DISTRIBUTION; SAFETY;

EID: 0346964397     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmri.10439     Document Type: Article

References (8)

1. Grossman RI, Rubin DL, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000;35:412-419.
2. Rubin DL, Desser TS, Semelka R, et al. A multicenter, randomized, double-blind study to evaluate the safety, tolerability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging 1999;9:240-250.
3. Shetty AN, Shirkhoda A, Bis KG, Alcantara A. Contrast-enhanced three-dimensional MR angiography in a single breath-hold: a novel technique. Am J Roentgenol 1995:165:1290-1292.
4. Wible JH, Jr, Galen KP, Wojdyla JK. Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs. Invest Radiol 2001;36:292-298.
5. Metropolitan Life Insurance Co. http://www.metlife.com/lifead-vice/tools/heightnweight.
6. Guideline for Good Clinical Practice, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Federal Register, May 9, 1997.
7. Swan SK, Baker JF, Free R, et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999;9:317-321.
8. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-1633.